Skip to Content

Hetlioz FDA Approval History

FDA Approved: Yes (First approved January 31, 2014)
Brand name: Hetlioz
Generic name: tasimelteon
Dosage form: Capsules
Company: Vanda Pharmaceuticals Inc.
Treatment for: Non-24-Hour Disorder

Hetlioz (tasimelteon) is a melatonin receptor agonist for the treatment of Non-24-Hour Disorder in the totally blind.

Development Timeline for Hetlioz

Jan 31, 2014Approval FDA Approves Hetlioz: First Treatment for Non-24 Hour Sleep-Wake Disorder in Blind Individuals
Nov 15, 2013FDA Advisory Committee Recommends Approval of Hetlioz for the Treatment of Non-24-Hour-Disorder (Non-24) in the Totally Blind
May 31, 2013Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.